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Abstract
Vaccine development against pathogenic bacteria is an imperative initiative as
bacteria are gaining resistance to current antimicrobial therapies and few novel
antibiotics are being developed. Candidate antigens for vaccine development can
be identiﬁed by a multitude of high-throughput technologies that were accelerated
by access to complete genomes. While considerable success has been achieved in
vaccine development against bacterial pathogens, many species with multiple
virulence factors and modes of infection have provided reasonable challenges in
identifying protective antigens. In particular, vaccine candidates should be
evaluated in the context of the complex disease properties, whether planktonic
(e.g. sepsis and pneumonia) and/or bioﬁlm associated (e.g. indwelling medical
device infections). Because of the phenotypic differences between these modes of
growth, those vaccine candidates chosen only for their efﬁcacy in one disease state
may fail against other infections. This review will summarize the history and types
of bacterial vaccines and adjuvants as well as present an overview of modern
antigen discovery and complications brought about by polymicrobial infections.
Finally, we will also use one of the better studied microbial species that uses
differential, multifactorial protein proﬁles to mediate an array of diseases,
Staphylococcus aureus, to outline some of the more recently identiﬁed problematic
issues in vaccine development in this bioﬁlm-forming species.
A history of bacterial vaccines
The ﬁrst bacterial vaccines developed used whole bacteria in
either a live, attenuated vaccine (LAV) or a killed, whole-cell
vaccine (KWCV). LAVs are generated either by repeat
passage of the pathogen in a nonstandard host or in culture
media or more recently by the targeted deletion of gene(s)
that enable a pathogenic phenotype in humans. Louis
Pasteur’s workon the chicken cholera bacterium (Pasteurella
multocida) and anthrax are the earliest examples of bacterial
LAVs. Subsequent research on bacterial LAVs led to the
development of the BCG vaccine for tuberculosis (Bastos
et al., 2009), the salmonella Ty21a vaccine for the prevention
of typhoid (Wahdan et al., 1980), and the CVD103-Hgr
vaccine against cholera (Ketley et al., 1993; Levine & Kaper,
1993). These vaccines continue to be used in developed and
developing countries, because LAVs often confer a robust,
long-lasting protection without the need to administer
frequent booster shots.
Salmon and Smith subsequently laid the foundation for
administering a heat-killed suspension of bacteria and paved
the way for KWCVs. These vaccines were easy to produce,
but had frequent adverse effects such as fever, anorexia, and
swelling or induration induced by lipopolysaccharide. These
drawbacks have led to almost complete clinical disuse of
KWCVs in the United States. In response to these side
effects, acellular, protein versions of traditional vaccines
such as the acellular pertussis vaccines (Decker & Edwards,
2000) and the acellular anthrax vaccines (Friedlander
& Little, 2009) followed. Rationales for immunizing with
a limited number of antigens are reduced reactogenicity
and avoidance of autoimmunity resulting from molecular
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Ymimicry by bacterial antigens (Zorzeto et al., 2009). A
limitation is that immunity elicited by a single antigen
wanes more quickly than that generated by a LAV.
Alternatively, the tetanus and diphtheria toxoid vaccines
developed in the 1920s are currently being used with minor
alterations to their manufacture (Plotkin et al., 2008). The
toxoid vaccine lacks the toxin’s pathogenic qualities and is
used for vaccination to generate neutralizing antibodies
against the toxin. Because single toxins are responsible for
the bulk of Clostridium tetani and Corynebacterium
diphtheriae pathogenesis, a robust immunoglobulin G
(IgG) neutralizing antibody response that targets and blocks
the toxin interrupts the disease process.
A better understanding of the critical role of polysacchar-
ide capsules in the pathogenesis of Streptococcus pneumoniae
and Haemophilus inﬂuenzae led to the development of
polysaccharide vaccines (PSVs) against these pathogens
(Riley et al., 1977; Robbins et al., 1983; Mufson et al., 1985)
as well as a PSVagainst Neisseria meningitidis serotypes A, C,
W-135, and Y (Artenstein et al., 1970; Armand et al., 1982;
Ambrosch et al., 1983). Because of suboptimal immuno-
genicity elicited by polysaccharide, PSVs are being elimi-
nated and replaced by polysaccharide–protein conjugate
vaccines. Conjugate vaccines elicit a robust IgG response
imparted by the protein carrier, which converts the poly-
saccharide from a T-cell-independent immunogen into a T-
cell-dependent immunogen (Perez-Melgosa et al., 2001).
Innovations to vaccine design over the years have resulted
in a number of successful bacterial vaccines that supplant
earlier, less effective vaccines. Currently, several competing
cholera (Lopez et al., 2008) and typhoid vaccines (Fraser
et al., 2007) are available. A closer examination of these
vaccines deﬁnes the pros and cons of certain vaccine
strategies (Table 1).
Although vaccinology has made signiﬁcant progress
(Table 2), many challenges remain to date. When dealing
with bacterial pathogens that can cause multiple forms of
diseases through a large number of virulence factors, often
traded between individual strains and species by horizontal
gene transfer, protection via a single component vaccine is
likely to be elusive. Staphylococcus aureus is an example of
such a pathogen. This microbial species has dozens of
known toxins, multiple immunoavoidance, and adherence
factors, most of which demonstrate transient, timed, and
disease-speciﬁc expression (DeLeo et al., 2009). Therefore, a
successful vaccine will likely be required to provide protec-
tive antibody titers against multiple antigens (Zecconi et al.,
2005).
Types and modes of delivery of vaccines
Recombinant subunit protein technology has become the
main strategy in the development of vaccines against
infectious diseases. Subunit vaccines offer several advantages
over previous vaccine strategies. Recombinant subunit vac-
cines are safe or less reactogenic with a deﬁned composition,
which is due to its genetic-based approach and antigen
expression in nonpathogenic bacterial strains. Other advan-
tages include multiple modes of delivery and further en-
gineering of the subunit (Liljeqvist & Stahl, 1999; Hansson
Table 1. General characteristics of classical bacterial vaccine types
Vaccine type Pros Cons
Killed, whole bacteria Relatively simple to make
Produces a protective immune response for many
organisms
Highly reactogenic in many cases, this has rendered vaccines
unusable or unpopular
Risk of induction of autoimmunity via molecular mimicry
Booster doses often needed
Live, attenuated bacteria More robust and longer lasting immunity relative to
killed, whole bacteria
Possibility of disease in immunocompromised patients
Possibility of reacquisition of lost virulence resulting in disease
Risk of secondary transmission
Toxoid Excellent at generating toxin neutralizing antibodies
Markedly less reactogenic compared with killed, whole
bacteria
Multiple doses often needed
Epitope must be highly conserved
Protein only Markedly less reactogenic compared with killed, whole
bacteria
Multiple doses often needed
Epitope must be highly conserved
Polysaccharide only Markedly less reactogenic compared with killed, whole
bacteria
Multiple doses often needed
Epitope must be highly conserved
Polysaccharide–protein
conjugate
Improved antibody titers relative to polysaccharide only
Decreased carriage for meningococcal and
pneumococcal vaccines
Can generate longer lasting immunity relative to
polysaccharide vaccines
Markedly less reactogenic compared with killed, whole
bacteria
Meningococcal conjugate vaccine not currently
recommended for children under age 11
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Pathogen (disease) Vaccine type Composition Current status
Bacillus anthracis (anthrax) Live, attenuated Sterne live-attenuated strains Not available in the United States for
humans, only for veterinary use
Acellular Cell-free culture supernatant adsorbed
to aluminum hydroxide; believed to
contain mostly the protective antigen of
the anthrax toxins
Not available to the public in the United
States
Bordetella pertussis (pertussis) Killed, whole cell Killed pathogenic bacteria Completely replaced by acellular
vaccine in the United States and many
developed countries
Acellular Inactivated pertussis toxin plus one or
more of the following proteins:
hemaglutinin, pertactin, or ﬁmbriae
types 2 and 3
Approved for clinical use in the United
States
Borrelia burgdorferi (Lyme disease) Killed, whole cell Inactivated whole-cell vaccine with
proprietary polymer adjuvant or bivalent
whole-cell killed
Veterinary vaccines for dogs
Lipoprotein Lyme OspA recombinant lipoprotein Withdrawn from clinical use in 2002
Clostridium tetani (tetanus) Toxoid Formaldehyde detoxiﬁed tetanus toxin Currently licensed in the United States
in several combinations
Corynebacterium diphtheriae
(diphtheria)
Toxoid Diphtheria toxoid adsorbed to
aluminum salt
Currently licensed in the United States
in several combinations
Coxiella burnetii (Q fever) Killed, whole cell Killed C. burnetii Not commercially available in the United
States
Haemophilus inﬂuenzae type B
(pneumonia and meningitis)
Polysaccharide Polyribosylribitol phosphate (PRP) Not effective in children younger than
18 months (the population that
experiences the most severe disease),
not currently used in the United States
Polysaccharide–protein
conjugate
PRP or HbOC linked to either diphtheria
toxoid or the outer membrane protein
complex of N. meningitidis
Four currently licensed conjugate
vaccines in the United States
Mycobacterium tuberculosis
(tuberculosis)
Live, attenuated Bacille Calmette-Geurin (BCG) Widespread global use; rarely
administered in the United States
Neisseria meningitidis (meningitis) Polysaccharide–protein
conjugate
Quadrivalent vs. A, C, Y, and W-135
strains
Currently licensed in the United States
Rickettsia rickettsii (typhus) Killed, whole cell Inactivated chick embryo cultured R.
rickettsii
No currently licensed vaccine in the
United States
Salmonella typhi (Typhoid) Killed, whole cell Heat- and phenol-inactivated S. typhi No longer available in the United States
Killed, whole cell Acetone inactivated parenteral vaccine Only available to the United States
Armed Forces
Live, attenuated Ty21a galactose nonfermenting S. typhi Available in the United States
Polysaccharide Vi capsular antigen Available in the United States
Polysaccharide–protein
conjugate (Vi-rEPA)
Vi capsular antigen conjugated to
Pseudomonas aeruginosa recombinant
exotoxin A
In development
Streptococcus pneumoniae
(pneumonia and meningitis)
Killed, whole cell Monovalent killed Abandoned, not available
Polysaccharide 6-, 14-, and 23-valent polysaccharide
vaccines
No longer used in the United States
because it couldn’t be used for children
o2 years old and superior protection
was afforded by conjugate vaccines
Polysaccharide–protein
conjugate
7-valent polysaccharide conjugated to
diphtheria
CRM197 carrier protein
Currently licensed for prevention of
infant and child meningitis
Polysaccharide 23-valent polysaccharide Licensed for the prevention of
pneumonia in patients of 65 years of
age or older or immunosuppressed
patients over the age of two
Vibrio cholerae (Cholera) Killed, whole cell Killed pathogenic bacteria Licensed, but not widely used
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requirement of an adjuvant and multiple doses as well as low
immunogenicity and a short half-life, which can be im-
proved by conjugating the protein subunit to another
protein or molecule (Hudecz, 2001; Tugyi et al., 2008).
Conjugation of an antibody, adhesion factor, or other
molecule (such as cholera toxin B subunit) to the peptide
can target it to immunologically relevant sites or cells to
improve response. Recombinant subunit vaccine efﬁcacy is
also reliant on the route of administration.
Current delivery methods include parenteral (e.g. trans-
cutaneous and intramuscular) and mucosal (e.g. intranasal
and oral) vaccines. The skin serves as a functional barrier by
preventing harmful molecules and organisms from invading
the host. Langerhans cells, a class of antigen-presenting cells,
present antigens in the epidermal layer and the accessibility
of the skin makes parenteral vaccination a favorable delivery
method. The parenteral route of vaccine delivery is an
effective inducer of systemic immunity represented by
signiﬁcant serum IgG titers and cytokine expression in
lymph nodes. Nevertheless, this mode of vaccine delivery is
deﬁcient in its ability to initiate a mucosal immune
response.
The mucosal surface is resident to the majority of
lymphocytes found in the human body and is also the main
entry point for infectious agents. This makes targeting
vaccines to the mucosal sites crucial for immunity. The
main advantage of mucosal vaccination over parenteral is
the induction of IgA secretion at mucosal sites in combina-
tion with systemic IgG titers. Secreted IgA prevents the
colonization and invasion of pathogens and neutralizes
toxins at the mucosa (Slutter et al., 2008). Mucosal vaccina-
tion leads to antigen-speciﬁc B cell memory, with the caveat
that a proper immunostimulating compound is used (Vajdy,
2006). Antigen delivered without an adjuvant leads to
mucosal tolerance, resulting in clonal deletion or induction
of anergy of antigen-speciﬁc lymphocytes (Ogra et al.,
2001). In addition to mucosal tolerance, inefﬁcient uptake
of antigen and delivery to antigen-presenting cells is another
disadvantage of mucosal vaccination (Slutter et al., 2008).
Mucosal vaccination has the potential to alleviate the
innumerable diseases caused by pathogenic bacteria, viruses,
and parasites by providing complete protection through
IgA-mediated mucosal and IgG-mediated systemic immu-
nity. Overcoming the hurdles of mucosal tolerance and
inefﬁcient antigen delivery may augment the vaccines cur-
rently in clinical trials.
Adjuvants
Adjuvants work by stimulating the innate immune response,
which is a required step in activating adaptive immunity.
Cytokines and chemokines expressed upon stimulation of
the innate immune response attract leukocytes to the local
environment and cause maturation of antigen-presenting
cells such as dendritic cells (DCs). The resident DCs are
effective messengers between the innate and the adaptive
response due to their enhanced antigen-presenting capabil-
ities and ability to become polarized. Adjuvants promote
cytokine expression within a microenvironment that po-
larizes DCs to mediate the expression of Th1 or Th2
cytokines and costimulatory molecules. In the draining
lymph nodes, polarized DCs present the antigen to naı ¨ve
T-cells. The development of Th0 to Th1, Th2, or other
T-helper cells during antigen presentation is dependent on the
expression of polarizing cytokines and costimulatory recep-
tors produced by DCs. T-cells activated during this process
potentiate the subsequent adaptive immune response.
Selecting the appropriate adjuvants for vaccine develop-
ment is crucial, because they play a critical role in the
development and polarization of the adaptive immune
response. Adjuvants have been found to favor either a Th1
or a Th2 response, suggesting the production of Th1- and
Th2-polarizing cytokines at the site of administration. To
Table 2. Continued.
Pathogen (disease) Vaccine type Composition Current status
Killed, whole cell plus
recombinant protein
(WC-rBS)
Two heat-killed strains of V. cholerae
plus recombinant cholera toxin B
Only approved for experimental use in
the United States
Live, attenuated
(CVD103-Hgr)
Pathogenic bacteria with the cholera
toxin B subunit deleted
Only approved for experimental use in
the United States
Yersinia pestis (Plague) Killed, whole cell
(Haffkine vaccine)
Heat-inactivated whole organism Generated severe AE’s, never widely
adopted
Killed, whole cell Formalin-inactivated Y. pestis Formerly licensed for sale and used in
military personnel during Vietnam War;
no longer available due to marked AE’s
to initial and booster doses
AE, adverse event; HbOC, Haemophilus b oligosaccharide conjugate (derivative of PRP); PRP, polyribosylribitol phosphate.
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whether it be Th1 or Th2, becomes essential in the selection
of an adjuvant for vaccine design. Few adjuvants exist in the
clinical realm; however, many are being tested experimen-
tally. Table 3 details supplemental information on the
current and experimental adjuvants.
Adjuvants are potent inducers of innate immunity. They
are often needed for an effective and protective adaptive
immune response against pathogens. The Th response
stimulated by vaccination is dependent on the cytokine
milieu produced locally by an adjuvant, and the resultant
polarization of antigen-presenting cells. Also, planktonic vs.
bioﬁlm-mediated diseases initiated by the same pathogen
complicate vaccine development as each phenotype may
require different Th responses to provide postvaccination
protection. Research on the immunostimulating properties
of molecules will elucidate future adjuvants and provide
even greater options for vaccine development.
Novel strategies for antigen selection:
highlighting S. aureus advances
Vaccine design changed dramatically with advancements in
genome sequencing technologies that enable rapid comple-
tion of genomes. Since the publication of the H. inﬂuenzae
genome in 1995, the NCBI genome project reports that 1026
complete microbial genomes have been published including
ones for 15 S. aureus strains (Fleischmann et al., 1995)
(http://www.ncbi.nlm.nih.gov/genomeprj). Access to com-
plete genomes and bioinformatic technologies to manage
and analyze the data has advanced high-throughput mole-
cular techniques for genomic, transcriptomic, and proteo-
mic analyses of microbial growth and pathogenesis (Kaushik
& Sehgal, 2008; Zagursky & Anderson, 2008). Genome-
based technologies provide rapid identiﬁcation of vaccine
candidates compared with the conventional vaccine ap-
proaches, which identify and analyze individual virulence
factors from pathogens grown in vitro (Rappuoli, 2000).
Vaccines developed via genome-based technologies will
still slowly transition into clinical phases after rapid identi-
ﬁcation, because these vaccines require the same rigorous
evaluations using in vitro assays and animal models
to validate functional activity as conventionally derived
vaccines. As this review focuses on vaccine development
against S. aureus to highlight in vivo phenotypes
(e.g. bioﬁlm formation and polymicrobial infection) that
should be considered during antigen identiﬁcation,
we choose to present genome-based strategies and other
technologies that identiﬁed putative S. aureus virulence
factors and/or vaccine candidates. Vaccines comprised of
antigenic candidates identiﬁed by these strategies may
provide protection against S. aureus infection, but the over-
all lack of an effective S. aureus vaccine to date indicates that
critical phenotypes and factors are not adequately addressed
in current vaccines. For the strategies outlined below, both
these and future studies examining alternate parameters will
Table 3. Adjuvant-dependent effector Tcell differentiation
Adjuvants Clinical status Immune response
Experimental observations to
designate immune response References
Alum Only one approved for
US vaccines
TH2 TH1 No IgG2a titer
No IFN-g
Uddowla et al. (2007)
Brewer (2006)
TH2 High IgG1 titer
IL-4 and IL-5 produced
Uddowla et al. (2007)
Brewer (2006)
MF59 Fluad inﬂuenza
vaccine
TH2 TH1 Low IgG2a titer Valensi et al. (1994), Wack et al.
(2008)
TH2 High IgG1
IL-5, IL-4, and THF-a produced
Valensi et al. (1994), Wack et al.
(2008)
MF59 with CpG No clinical application
w TH1 TH1 High IgG2a titer
IFN-g produced
Wack et al. (2008)
TH2 Low IgG1 titer
IL-5 suppressed
Wack et al. (2008)
AS04 Cervarix
(HPV)–Fendrix
(Hepatitis B)
TH1 TH1 High IgG2a
IL-2 and IFN-g produced
Korsholm et al. (2010), Didierlaurent
et al. (2009)
TH2 Low IgG1
IL-6 and THF-a produced
Korsholm et al. (2010), Didierlaurent
et al. (2009)
c-di-GMP No clinical application
w TH1/TH2 TH1 High IgG2a and IgG2b
IFN-g,T H F - a,
IL-12, MCP-1, and RANTES produced
Karaolis et al. (2007), Hu et al. (2009)
TH2 High IgG1 and IgG3 Hu et al. (2009)
European-approved vaccine application only.
wNot approved for human vaccine applications.
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candidates.
Genomics/transcriptomics
Identiﬁcation of vaccine candidates through the systematic
search of the genome and identiﬁcation of putative antigens,
mainly surface-associated proteins, using bioinformatics is
referred to as ‘reverse vaccinology’ (Rappuoli, 2000). The
progression of this ﬁeld and its signiﬁcance to vaccine
development against serogroup B N. meningitidis and group
B Streptococcus are detailed in reviews by Serruto & Rappuo-
li (2006), Serruto et al. (2009). This method has a number of
advantages compared with previously used methods in that
there is no need to grow the pathogen in vitro and antigen
selection can proceed independent of the abundance of
in vivo expression and immunogenicity. As a result, many
unique antigens can be tested that would have been passed
over in conventional studies.
Vaccine candidates identiﬁed from a single genome in
reverse vaccinology must provide in vivo protection against
multiple clinical strains in correlative animal models to
support transition into clinical studies. An approach, known
as comparative genomic hybridization (CGH), uses a DNA
microarray of a sequenced ‘reference’strain to screen for the
presence or absence of genes within nonsequenced ‘test’
strains and limits the candidates to antigens conserved in
multiple strains. However, the modern ability of advanced
sequencing methods such as pyrosequencing has enabled
whole-genome sequencing for multiple genomes from var-
ious strains of a microbial species to become commonplace.
Access to complete genomes of multiple strains for some
bacteria makes sequence comparisons among multiple gen-
omes a favorable alternative to CGH because the compar-
ison accounts for all genes within each strain. Earlier CGH
studies and more recent deep strain sequencing have led to a
description of the ‘pangenome’ in three parts: a ‘core’
genome comprised of genes conserved in all genes, a
distributed genome composed of genes not conserved in
one or more strains, and a subgroup comprised of novel
genes encoded by a single strain (Tettelin et al., 2002, 2005;
Shen et al., 2005; Ehrlich et al., 2008). A protective quad-
rivalent vaccine for S. aureus was assembled from surface
proteins, IsdA, IsdB, SdrD, and SdrE, after searching eight
genomes and evaluating the protective efﬁcacy of multiple
candidate antigens in mice (Stranger-Jones et al., 2006).
The increased access to complete genomes of bacteria has
led to the ability to develop unique cDNA microarrays for
transcriptomic proﬁling. Evaluation of the bacterial tran-
scriptome under in vitro conditions, mimicking environ-
mental stimuli encountered during host infection, detects
upregulated genes that may represent virulence factors and
vaccine candidates. Transcriptomic analysis is generally
restricted to in vitro studies, because bacterial RNA is
difﬁcult to extract differentially from the infected host
tissue.
Gene expression technologies: positive
selection
Other technologies make use of the in vivo transcriptional
proﬁles to gather information on the genes involved in
virulence, but circumvent the restrictions of RNA extraction
and microarray analysis. Three techniques that analyze in
vivo gene expression and predict promising vaccine candi-
dates are in vivo expression technology (IVET), differential
ﬂuorescence induction (DFI), and in vivo induced antigen
technology (IVIAT) (Mahan et al., 1993; Valdivia & Falkow,
1996; Handﬁeld et al., 2000).
The ﬁrst report of IVET applied to a Gram-positive
species was a study of S. aureus by Lowe et al. (1998), using
a variation known as recombination-based IVET (RIVET).
In the RIVETsystem, random genomic fragments are fused
to a promoterless resolvase gene, such as tnpR, to construct a
genomic library, and a gene cassette comprised of an
antibiotic resistance gene ﬂanked by resolvase recognition
sequences is incorporated into the bacterial genome. Exci-
sion of the antibiotic marker from the bacterial genome, or
‘resolution’, is dependent on the expression of the ivi gene-
resolvase fusion, and confers antibiotic sensitivity to the
bacterium (Angelichio & Camilli, 2002). Lowe et al. (1998)
assessed 11 mutants for ivi genes that were identiﬁed from
S. aureus genomic libraries screened in a murine renal
abscess model and deﬁned seven mutants with attenuated
virulence compared with wild-type S. aureus. DFI is another
promoter-trap approach where promoter induction con-
trols the expression of green ﬂuorescent protein, and micro-
organisms with gene expression can be isolated by
ﬂuorescence-activated cell sorting (Valdivia & Falkow,
1996). Finally, the IVIAT system screens in vitro expression
libraries of a pathogen with convalescent sera following
depletion of antibodies speciﬁc to that pathogen grown
under in vitro conditions.
Gene expression technologies: negative
selection
Signature-tagged mutagenesis (STM) identiﬁes the genes
required for in vivo growth and survival by screening
heterogeneous pools of mutants. Each of the mutants has a
transposon with a unique oligonucleotide tag randomly
incorporated into their genome. After inoculating pools of
mutants into a relevant in vivo infection model, those
mutants that fail to colonize the model can be identiﬁed by
their unique transposon tag (Hensel et al., 1995). STM
screens of S. aureus virulence in murine models of bacter-
emia, abscess, and wound and rabbit endocarditis have been
FEMS Immunol Med Microbiol 59 (2010) 306–323 c  2010 Federation of European Microbiological Societies
Published by Blackwell Publishing Ltd. All rights reserved
311 Vaccines and bioﬁlmscompleted, and report that o10% of the mutants were
attenuated in all three murine models (Mei et al., 1997;
Coulter et al., 1998).
Proteomics
Proteomic proﬁling examines and identiﬁes the spectrum of
proteins expressed in bacteria under varying growth condi-
tions using two-dimensional gel electrophoresis (2DGE)
and MS. Detection of membrane and cell wall proteins is a
limitation of proteomic proﬁling due to low abundance and
solubility constraints that are caused by protein hydropho-
bicity, transmembrane domains, and an alkaline isoelectric
point (Fountoulakis & Takacs, 2001). Because vaccine
strategies focus on surface-associated proteins, proteomic
analyses yield limited vaccine candidates unless extraction
protocols that solubilize membrane proteins or isoelectric
focusing performed in the alkaline pH range are used.
Reference maps of S. aureus Phillips and VISA surface
proteomes following lysostaphin extraction have been pub-
lished, and among these, membrane- and cell wall-asso-
ciated proteins are promising candidate antigens that can be
tested for immunogenicity and/or protective activity (Nan-
dakumar et al., 2005; Gatlin et al., 2006). Another strategy,
considered a ‘new chapter in reverse vaccinology,’developed
concurrently with the cited work of Nandakuman and
colleagues, and Gatlin and colleagues examined surface
proteins ‘shaved’ from group A Streptococcus using trypsin
disgestion (Musser, 2006; Rodriguez-Ortega et al., 2006).
Cell surface shaving proteomics has recently established 42
S. aureus COL surface proteins that may have potential for
vaccine development (Solis et al., 2010).
Serological probing of proteomic samples, known as
immunoproteomics, followed by peptide identiﬁcation
using matrix-assisted laser desorption ionization time-of-
ﬂight MS is a direct method for deﬁning antigenic proteins.
An initial 2DGE immunoproteomic study of S. aureus COL
identiﬁed 15 known and novel proteins that were immunor-
eactive with patient sera (Vytvytska et al., 2002). Using
subtractive proteome analysis, Glowalla and colleagues
selected proteins that were immunoreactive with an intrave-
nous immunoglobulin (IVG) preparation and nonreactive
with IVG depleted of S. aureus-speciﬁc opsonizing antibo-
dies and identiﬁed three anchorless cell wall proteins that
provided partial protection in a mouse sepsis model (Glo-
walla et al., 2009). These anchorless wall proteins lack a
conserved signal peptide or an LPXTG motif, characteristic
of most surface-associated proteins, and in some cases, may
be consequently omitted from classical reverse vaccinology
screens (e.g. vaccine development from genome analysis)
(Chhatwal, 2002). Immunoproteomic studies have also
evaluated two obstacles to the clinical control and preven-
tion of S. aureus, bioﬁlms that potentiate chronic infections
and colonization or human carriage (Brady et al., 2006;
Holtfreter et al., 2009). Indeed, most humans possess pre-
existing circulating antibodies against major S. aureus
virulence factors that do not protect against a subsequent
challenge by this pathogen. Incomplete protection may be
attributed to the transient nature of virulence factor expres-
sion during the infection, which requires consideration
during the process of vaccine development.
Antigenomics
Antigenomic screens probe Escherichia coli surface-ex-
pressed fusions that express randomly fragmented genomic
libraries with human sera that are depleted of E. coli-speciﬁc
antibodies. The screens identify a large repertoire of anti-
genic peptides including those encoded by alternate reading
frames (Etz et al., 2002). Indeed, antigenomic studies of
Staphylococcus and Streptococcus found that 24% of antigens
were hypothetical proteins or proteins of unknown function
from nonannotated reading frames (e.g. alternative reading
frame, complementary strand reading frame, nongene
matching reading frame), which are categories eliminated
from bioinformatics-based vaccine development (Meinke
et al., 2005). Antigenomic peptides can be evaluated for
widespread in vivo expression, or reactivity, via screening
with multiple serum samples and conserved expression
among multiple bacterial strains (Etz et al., 2002). High-
throughput screening methods that circumvent the restric-
tive in-frame cloning step and peptide insolubility issues
that limit peptide repertoire in the bacterial surface expres-
sion systems include phage display and ribosome display.
However, antigenomic strategies may inadequately deﬁne
antigenic peptides compared with in vitro expression sys-
tems, possibly due to protein toxicity and reduced mem-
brane permeation obstructing surface expression and
limiting antigen detection.
Taking into account the mode of growth: biofilm
vs. planktonic
The early pioneering work and the continued modern era of
bioﬁlm disease discovery by a number of investigators have
transformed the ﬁeld of medical microbiology (Nickel et al.,
1985a,b, 1986a,b, 1989; Post et al., 1996; Ehrlich et al., 2002;
Erdos et al., 2003; Murphy et al., 2005; Stoodley et al., 2005;
Hall-Stoodley et al., 2006; Hiller et al., 2007; Hogg et al.,
2007). Because of these studies, the bioﬁlm mode of growth
has been recognized as the major mode of infection, with
an estimated 80% of all infections caused by bioﬁlms
(National Institutes of Health, 1998, 1999). Although exten-
sive studies have been performed on bioﬁlm infections, the
resolution of these infection continues to be the surgical
removal of the nidus of infection (Shirtliff & Mader, 2000).
This surgical removal is necessary because these microbial
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bial agents than their planktonic and free-ﬂoating counter-
parts (Nickel et al., 1985b; Stewart & Costerton, 2001).
Although the signiﬁcance of bioﬁlm infections has been
recognized as an important mediator of chronic infection
and the resulting morbidity and mortality, vaccine studies
have often ignored bioﬁlms in discovery and efﬁcacy studies.
For example, recent vaccine development programs for
S. aureus have tended to focus on testing the ability of target
antigens to protect the host from in vitro or murine
planktonic infection models (Fattom et al., 1996, 2004;
McKenney et al., 1998, 1999, 2000; Stranger-Jones et al.,
2006; Bubeck Wardenburg & Schneewind, 2008; Lin et al.,
2009; Kimet al., 2010). Infections with S. aureus mayexist in
a bioﬁlm mode of growth either during nares carriage or
skin infections. Once transmitted to the circulatory system
through an epithelial breach, planktonic growth ensues,
where upregulation of adherence factors occurs (Beenken
et al., 2004). At this point, the invading staphylococci are
either removed by the host innate immune response or
attach to host extracellular matrix proteins and develop a
localized bioﬁlm community. Once this community devel-
ops, the proteome of the microorganisms quickly trans-
forms into a bioﬁlm phenotype. Therefore, the planktonic
mode of growth that occurs in sepsis may be a transient
state. Also, although the host may be vaccinated against
planktonic antigens, they may develop a signiﬁcant memory
response only after the secondary foci of bioﬁlm infection
has already occurred and the antigenic nature of this
pathogen has also signiﬁcantly changed, thereby detracting
from vaccine efﬁcacy.
In the context of bioﬁlm infections, the ﬁrst question that
must be answered when selecting antigen targets is which
component of the bioﬁlm should be targeted. Broadly
speaking, two alternatives exist: bacterial cells within the
bioﬁlm and the bioﬁlm matrix itself. The bioﬁlm matrix
may be composed of polysaccharides, protein, or extracel-
lular DNA, in proportions that vary between bacterial
genera, species, and strains. As of 2009, the majority of
antibioﬁlm vaccine efforts have been directed toward the
bioﬁlm matrix (Schaffer & Lee, 2008). Perhaps the best
example of this is the staphylococcal polysaccharide inter-
cellular adhesin (PIA), which is composed of poly-N-acetyl-
b-1,6-glucosamine (PNAG). The enzymes that catalyze the
production of these polysaccharides are encoded for by the
genes of the icaADBC locus (Joyce et al., 2003). PIA is
produced by both Staphylococcus epidermidis (McKenney
et al., 1998) and S. aureus (Cramton et al., 1999), and is
known to be involved in the adherence of S. epidermidis to
both host tissues (Costa et al., 2009) and inert biomaterials
(Olson et al., 2006). PIA/PNAG plays an additional role in
immune evasion in both the bioﬁlm and the planktonic
mode of growth. The icaADBC locus has been detected in
clinical S. epidermidis isolates (Ziebuhr et al., 1997), and its
contribution to pathogenesis has been demonstrated in
animal models of infection (Rupp et al., 1999). Hence, upon
a superﬁcial review, PIAwould seem to be an ideal candidate
for a vaccine antigen.
In contrast to S. epidermidis, PIA production is less
pronounced in most S. aureus strains and often observed in
vitro only under particular conditions, such as anaerobiosis
(Cramton et al., 2001) or relatively high (1%) glucose
concentrations (Ammendolia et al., 1999). In one study,
only 57% of strains that were icaADBC positive by PCR
analysis (Arciola et al., 2001a) produced a bioﬁlm when
cultured in vitro (Knobloch et al., 2002), suggesting distinct
strain differences in any correlation of PIA and bioﬁlm
formation. In vivo, analysis of clinical S. aureus isolates from
prosthetic-joint infections, bacteremia (Fowler et al., 2001),
catheter-related infections (Arciola et al., 2001a), or from
randomly selected clinical isolates (Martin-Lopez et al.,
2002) indicates possession of the ica locus by the majority
of isolates. However, a lack of PIA production was observed
in many of these strains in vitro. The proportion of ica-
positive strains among S. aureus clinical isolates is thought
to vary according to the clinical origin of the isolate and
even between infection sites that are both bioﬁlm mediated.
For example, the proportion of icaADBC-positive S. aureus
strains was higher in orthopedic prosthesis-associated infec-
tion (92%) than in catheter-associated infections (63%)
(Rohde et al., 2001). Thus, the site and composition of
indwelling biomaterials may act as selective factors for
strains with different and alternate adhesion mechanisms.
The situation is further complicated by the fact that posses-
sion by a staphylococcal strain of the icaADBC locus does
not necessarily mean that PIA will be produced in vivo.
Similarly, the production of PIA in vitro does not mean that
it will be produced in vivo during an infection. In addition,
in vitro PIA expression may differ between assays (Rohde
et al., 2001). Although there is some evidence that suggests a
correlation between icaADBC possession and slime produc-
tion in vitro (Arciola et al., 2001b), more research is required
to fully understand the importance of PIA in staphylococcal
infection in vivo. There is also limited evidence that suggests
that PIA expression can undergo phase variation (Ziebuhr
et al., 1997).
A vaccine based on PIA has undergone trials in animal
models. McKenney et al. (1998) used PNAG to immunize
mice. Five days after an intravenous challenge with two S.
aureus strains (CP5 Reynolds and CP8 MN8), both of which
are negative for PNAG production in vitro, immunized mice
showed a signiﬁcant reduction in CFU recovered from the
kidneys as compared with the controls (McKenney et al.,
1999). Further work by the same group suggested that the
deacetylated form of PNAG, dPNAG (15% acetylation),
conjugated to the diphtheria toxoid is more effective as a
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2005). This is likely due to the retention of dPNAG on the
bacterial cell surface, in contrast to the highly acetylated
PNAG form, which is released into suspension (Cerca et al.,
2007). The deacetylase activity of the icaB gene product
(Vuong et al., 2004) mediates this effect. The use of PNAG as
a vaccine has shown promise in subsequent studies in
animal models of S. aureus mastitis (Perez et al., 2009) and
S. aureus skin abscess (Gening et al., 2010). Given that
PNAG is produced by a variety of other bacterial taxa,
including E. coli (Wang et al., 2004), Actinobacillus actino-
mycetemcomitans, Actinobacillus pleuropneumoniae (Kaplan
et al., 2004), Bordetella spp. (Parise et al., 2007), and
Acinetobacter baumannii (Choi et al., 2009), PNAG has
shown promise in subsequent vaccine studies in animal
models of E. coli bacteremia (Cerca et al., 2007) and
peritonitis (Gening et al., 2010).
The efﬁcacy of a PNAG-based vaccine against S. aureus
bioﬁlm-type infection remains to be elucidated. However,
given that possession of the icaADBC locus by clinically
isolated S. aureus varies between infection sites (Rohde et al.,
2001), PNAG may not be the ideal vaccine antigen in a
formulation intended to prevent bioﬁlm-type infections.
Besides PIA/PNAG, other bioﬁlm factors have simply not
been evaluated extensively and these may potentially be
inappropriate targets in subsequent studies. Also, one may
question whether it would be more efﬁcacious to promote
the host immune response to attack the cells producing the
matrix or attack the matrix itself. The extracellular matrix of
a bioﬁlm community exists, at least in part, to act as an
immunoavoidance mechanism. Furthermore, in many
cases, the matrix material is constantly being produced and
sloughing off into the environment.
Polymicrobial diseases: considerations for
vaccine development
Although many infectious diseases are initiated by a single
pathogen or virulence factor, others originate from or are
attributed to a complex milieu of microorganisms. Exam-
ples of diseases associated with both polymicrobial and
bioﬁlm phenotypes include periodontal disease, otitis med-
ia, rhinosinusitis, ventilator-associated pneumonia, and
chronic wound infections (Brogden et al., 2005). These
bioﬁlm consortia of microorganisms typically coexist as
combinations of highly structured communities of bacteria,
viruses, protozoans, and fungi attached to biotic and
environmental surfaces, where their architecture is facili-
tated by speciﬁc intermicrobial and host interactions (Baka-
letz, 1995; Viale & Stefani, 2006; Kuramitsu et al., 2007).
Many of these interactions are mutually beneﬁcial for both
the host and the microorganism (e.g. the gastrointestinal
and oral microbiota). However, microbial species popula-
tion shifts and waning host immunity can allow coloniza-
tion and subsequent infection by opportunistic pathogens
that exploit unique niches in the polymicrobial environment
(Stecher & Hardt, 2008). Despite the challenges of imple-
menting polymicrobial vaccines, several have been at-
tempted and proven successful, while others have yielded
unexpected ﬁndings.
Traditionally, the guidelines for vaccine development for
monomicrobial infections often rely heavily on molecular
Koch’s postulates, such that directing an immune response
against a single virulence or colonization factor will provide
protection against disease (Falkow, 1988). Although these
rules have proven invaluable for vaccination against several
diseases (e.g. C. diphtheriae), they do not adequately con-
sider the pathogenesis of polymicrobial infections. It has
been well documented that bioﬁlm communities demon-
strate a signiﬁcantly different repertoire of gene and protein
expression as compared with their planktonic counterparts
(Dykes et al., 2003; Waite et al., 2006). However, little is
known about the transcriptomic and proteomic proﬁles of
multispecies bioﬁlms assessed against monomicrobial com-
munities. The pleiotropic effects of intermicrobial interac-
tions on the individual disease-causing pathogens and the
infected host are only now being appreciated. A recent study
by Sibley et al. (2008) used a Drosophila polymicrobial
disease model and luciferase reporter assay analyses to
examine the effects of human oropharyngeal commensal
isolates in coculture with Pseudomonas aeruginosa during
infection. The results from this study demonstrated that the
virulence of P. aeruginosa could be substantially enhanced or
reduced dependent on the presence of a coinfecting micro-
organism that was nonpathogenic independently. Even
more surprising was the modulation of host antimicrobial
and innate immunity genes due speciﬁcally to polymicrobial
vs. monomicrobial infection. These altered microbial and
host proﬁles are likely due to the unique physical interac-
tions and chemical signaling events that occur during the
development of polymicrobial communities (Hogan et al.,
2004; Bamford et al., 2009). Therefore, antigenic targets
should be screened in vivo, via biologically relevant routes of
infection or colonization, to ensure that immunogenic
proteins of interest are expressed during infection and in
the context of a polymicrobial environment as has been
described previously (Rollenhagen et al., 2004; Brady et al.,
2006; Hagan & Mobley, 2007).
The impact of the polymicrobial nature of a disease
regarding colonization and infection should also be consid-
ered during vaccine development. A disease must ﬁrst be
classiﬁed as truly polymicrobial based on sufﬁcient data
from clinical studies and epidemiological records. Impor-
tant criteria regarding the temporal shifts, composition,
abundance, and consistency of microorganisms present
throughout the entire course of the disease, from
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(Roberts, 1989; Tarsia et al., 2007). One must also distin-
guish contaminating microorganisms (pathogens or com-
mensals) from those that initiate and propagate infection. If
a disease is considered to be of a polymicrobial nature, a
vaccine composed of a multivalent cocktail of antigenic
proteins from all microorganisms involved in disease
pathology may be warranted. Although seemingly trivial,
these criteria are crucial to understanding the pathogenesis
of and developing effective vaccines for multimicrobial
diseases.
Polymicrobial infections represent a signiﬁcant complex-
ity in vaccine development. Two (or more) microorganisms
may act synergistically or antagonistically to mediate disease
while either in isolation is differentially virulent or benign
(Carlson, 1983; Diebel et al., 1999). Even if a vaccination
attempt successfully negates a necessary virulence factor for
one pathogen (i.e. a toxin), virulence could be complemen-
ted in trans by another factor produced by a neighboring
species in the polymicrobial community. In addition, the
eradication of one species from the polymicrobial commu-
nity may be insufﬁcient at reducing overall disease, as
another organism present may ﬁll in the niche left behind.
Alternately, a vaccination attempt targeting a virulence
factor (i.e. an adhesin) for one pathogen may successfully
target and eradicate a secondary pathogen within the poly-
microbial infection.
Modulation of a microorganism’s pathogenicity by the
polymicrobial community has important implications for
vaccine development as studies for S. aureus suggest. A
formidable nosocomial pathogen, S. aureus can be isolated
as the single etiologic agent in a multitude of diseases (e.g.
sepsis, lower respiratory tract infections, skin infections, and
others) or among a polymicrobial community in the same
disease types. Polymicrobial infections complicate approxi-
mately 27% of nosocomial Candida albicans bloodstream
infections; among these, S. aureus is the third most common
coinfecting microorganism (Klotz et al., 2007). As microbial
bioﬁlms on indwelling medical devices act as a potential
nidus for planktonic release and onset of sepsis, observa-
tions of enhanced bioﬁlm formation and differential matrix
composition for S. aureus in coculture with C. albicans
suggest that polymicrobial interactions may facilitate S.
aureus colonization and disease onset (Harriott & Noverr,
2009). The synergistic action of C. albicans and S. aureus has
also been implicated in the increased mortality of mice
infected with S. aureus strains producing the toxic shock
toxin (Carlson, 1983). Indeed, vaccination against C. albi-
cans using the candidal adhesion Als3P can provide cross-
kingdom protection against C. albicans and S. aureus, and
has positive implications for controlling diseases mediated
by coinfection of these microorganisms (Spellberg et al.,
2008).
In summary, polymicrobial infections require ecological
and physiological characterization to determine interac-
tomes and changes in target expression based on community
characteristics. Therefore, vaccine design for polymicrobial
infections should adequately consider the consortia of
microorganisms responsible for disease, potential inter
microbial interactions resulting in the modulation of in vivo
expressed antigens, and the strategic elimination of micro-
organisms that enhance or contribute to pathogenesis.
Future strategies may be to target vaccination against see-
mingly nonpathogenic organisms that facilitate increased
pathogenicity and colonization of virulent microorganisms.
Of course, vaccination against ‘commensals’ may have dele-
terious immunological and microbiological consequences
in the host and will have to be tested rigorously before
utilization.
Considerations for future vaccines:
lessons learned from S. aureus
Effective vaccines are available today for many previously
problematic bacterial infections, such as the triple vaccine
against C. diphtheriae, C. tetani, Bordetella pertussis (Pichi-
chero et al., 2006), N. meningitidis (Trotter et al., 2008), and
S. pneumoniae (Bernatoniene & Finn, 2005). The infections
targeted by these vaccines are all mediated by one or a few
virulence factors, which, when blocked or otherwise neutra-
lized, prevents pathogenesis. Alternatively, other microor-
ganisms have presented a signiﬁcant challenge in vaccine
development due to a complex disease process and the
presence and expression patterns of their respective viru-
lence factors. One such example is S. aureus. This patho-
genic species is able to cause a host of different types of
infections that are either planktonic (e.g. sepsis and pneu-
monia), bioﬁlm mediated (e.g. osteomyelitis, endocarditis,
chronic skin infections, indwelling medical device infec-
tions, chronic rhinosinusitis, dental implantitis, and en-
dophthalmitis), or a combination of both modes of growth
(e.g. abscess).
Staphylococcus aureus is able to accomplish this array of
infections by possessing nearly 70 virulence factors, each
with infectious mode-of-growth and time-speciﬁc expres-
sion patterns. Therefore, the search for a single candidate
antigen effective in all these cases has hindered S. aureus
vaccine development. Additionally, the ability of these
vaccines to provide protection against multiple modes of
growth, including both planktonic and bioﬁlm infection,
has not been addressed adequately. While the suggestion of a
prophylactic vaccine against the bioﬁlm mode of growth
seems counterintuitive, details emerging about S. aureus
pathogenicity and modulation of the host immune response
support this concept. In addition to the multitude of innate
immunity evasion tactics (e.g. inhibition of neutrophil
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of leukocyte levels, and inhibition of phagocytosis) (Foster,
2005), in vitro and in vivo studies indicate that S. aureus
factors direct the host response toward a beneﬁcial one for
the pathogen. In vitro cytokine analyses demonstrate a
robust Th1 immune response elicited against S. aureus:
staphylococcal enterotoxin B induces IL-2 and IFN-g (As-
senmacher et al., 1998), staphylococcal enterotoxin B in-
duces THF-a and MIP-1b (Dauwalder et al., 2006), and
whole-cell S. aureus induces IL-12 p70 and IL-18 (Buzas
et al., 2004). Studies in a murine model of prosthetic
implant infected with S. aureus found upregulation of Th1
cytokines (IL-2, IL-12 p70, and TNF-a) and Th17 cytokines
(IL-6 and IL-17) at days 7 and 28 postinfection and
increased levels of IgG2b (the dominant Th1-dependent
iso-subtype) compared with IgG1 (a Th-2 dependent iso-
subtype) in the serum at day 7 postinfection (R. Prabhakara
& M. E. Shirtliff, unpublished data). These studies indicate
that S. aureus elicits a prolonged Th1 response, where the
proinﬂammatory defenses are thwarted by the microbial
virulence factors and cause signiﬁcant damage to the host
tissue, and subverts a Th2 humoral response; these skewed
immune responses allow the planktonic S. aureus to elude
clearance by the immune system as the microorganism
colonizes the damaged host tissue and forms a bioﬁlm.
Therefore, in order to encompass all aspects of staphylococ-
cal virulence in vaccine development, one must also include
an emphasis on bioﬁlms.
Antigen selection: the next generation
In order to correctly select appropriate antigens that will be
effective in preventing the establishment of a microbial
infection, it is necessary to take into account the planktonic
and bioﬁlm modes of growth. Microbial bioﬁlms present a
unique challenge to researchers seeking to develop vaccines
against microorganisms whose infectivity depends, wholly
or in part, on this growth modality. Success cannot be
achieved by ignoring the fundamental principle of microbial
bioﬁlms: bioﬁlm-resident bacterial cells exhibit a phenotype
that is distinct, and in some cases, almost unrecognizable,
compared with that of taxonomically identical cells growing
planktonically (Beenken et al., 2004; O’May et al., 2009).
Thus, both the planktonic and the bioﬁlm phenotype
and its implications for antigen expression must be taken
into account during the selection of antigens to be included
in a vaccine. While the search for a single antigen that
provides multimodal protection may prove successful, it
seems more likely that a multicomponent vaccine will be
necessary. This is the ﬁrst criterion for an effective broad-
range vaccine.
The second is to ensure that the selected antigens are
expressed in all relevant strains of the pathogen targeted by
the vaccine. The genetic variation of surface-expressed
proteins between strains also raises a difﬁculty. Just such a
problem (Thompson et al., 2003; Dyet & Martin, 2005) as
well as the structural homology of the polysaccharide
capsule with the polysialylated form of the neural cell
adhesion molecule (Finne et al., 1983) has held up the
development of a broad-range vaccine against type B N.
meningitidis, although clinical trials have begun on vaccines
developed by reverse vaccinology and other strategies
(Granoff, 2010; Sadarangani & Pollard, 2010). For this
reason, it is vital to test vaccine efﬁcacy against as large a
number of strains as is realistically feasible.
The third principle is to ensure that the candidate
antigens are expressed in vivo throughout the infection cycle
in the multiple types of infection (e.g. sepsis vs. indwelling
medical device infection) for which the pathogen is the
identiﬁed etiological agent. Once again, like the multiple
modes of growth, this protection will most likely need to be
accomplished by a multivalent vaccine.
The fourth principle of antigen selection is that either (1)
the selected antigen, or (2) the sum of all antigens included
in a multicomponent vaccine, must be expressed through-
out the infecting microbial population. This is particularly
the case when prevention of bioﬁlm-type infections is the
goal. Bioﬁlm communities are inherently complex systems,
usually existing in close proximity to a surface. This com-
plexity arises from a number of factors. First, distinct
physicochemical gradients are found within microbial bio-
ﬁlm communities. In most cases, organic compounds,
oxygen, or water enter the bioﬁlm from the surrounding
bulk ﬂuid and diffuse through the matrix to the depths
closer to the surface. Bacteria resident within a bioﬁlm
consume these compounds at varying rates, resulting in
differential availability of nutrients, dependent on the loca-
tion of a particular cell within the community. This effect
has been observed experimentally in the case of oxygen
tension (de Beer et al., 1994). The situation is further
complicated by very low metabolic levels and radically
downregulated rates of cell division of the deeplyentrenched
microorganisms (Brown et al., 1988), including totally
nondividing ‘persister’ cells (Harrison et al., 2005; Lewis,
2008). This lowered growth rate is partially responsible for
the increased recalcitrance to antimicrobials exhibited by
bioﬁlm-embedded bacteria (Gilbert et al., 2002). The end
result of this is that cells in different areas of the bioﬁlm
exhibit spatial phenotypic heterogeneity, i.e. an antigen
expressed by cells in a relatively nutrient-rich area of the
community may not be expressed by other cells under less
favorable growth conditions. A study by Brady et al. (2006)
on S. aureus investigated the ability of polyclonal IgG raised
in rabbits against antigens, shown in an earlier work by the
same authors to be expressed in S. aureus bioﬁlm in vivo,t o
visualize S. aureus bioﬁlm communities grown in an in vitro
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although each of the four antigens was expressed within S.
aureus bioﬁlm communities, none of them was expressed
homogenously throughout the bioﬁlm. Instead, differing
expression patterns were observed for each antigen. Hence,
inclusion of any one antigen in a monovalent vaccine would
likely mean that only a fraction of the bioﬁlm would be
targeted and the bioﬁlm would likely survive and the
infection would persist. It follows that a multivalent vaccine
is essential when prevention of bioﬁlm-type infection is the
goal.
Finally, the antigens selected for a bioﬁlmvaccine must be
immunologically relevant, meaning that they must be cell-
surface proteins that are visible to the humoral immune
system and not obscured by the bioﬁlm matrix. Further-
more, each component must be capable of not only eliciting
a strong humoral immune response in the host, but a correct
response. In some cases, microbial clearance can be pro-
moted by either an inﬂammatory response (Th1 and/or
Th17) or an anti-inﬂammatory response (Th2 and/or Treg)
that can be disease mode, species, or even microbial strain
speciﬁc. Once again, multivalent vaccines seem to be re-
quired to accomplish this principle.
Brady and colleagues used these criteria to select four
protein antigens that were demonstrably expressed during
S. aureus bioﬁlm growth in vitro, cell-surface associated, and
immunogenic in the rabbit model of osteomyelitis (Mader
& Shirtliff, 1999; Brady et al., 2007). Singly, combined with
the TiterMax
TM adjuvant comprised of squalene, sorbitan
monooleate 80, and a synthetic block copolymer CRL8941,
these antigens were unable to provide protection against S.
aureus osteomyelitis in the rabbit model. However, when
used together as a prophylactic quadrivalent vaccine (75mg
of each protein administered subcutaneously; one booster
14 days later; both using the TiterMax
TM adjuvant) and
combined with postinfection vancomycin treatment
(5mgkg
1 twice daily for 10 days) to eliminate planktonic
bacteria residing within the bone, eight of nine animals
cleared the infection completely. Furthermore, there were
signiﬁcant reductions in radiological and clinical signs of
infection in the treated vs. the untreatedgroups(Brady etal.,
in press). Research now being conducted is seeking to
include S. aureus surface proteins expressed during plank-
tonic growth in order to remove the need for concurrent
vancomycin administration.
The unique physiology and properties of bioﬁlm must be
taken into account when selecting antigens for inclusion in
any vaccine intended to be effective against these commu-
nities. Bioﬁlm-type infections can no longer be regarded as
merely ‘bacteria embedded within slime’. Bioﬁlm-resident
microorganisms are distinct from their free-living counter-
parts and present unique challenges to anyone seeking to
develop novel prophylactic therapeutics.
Conclusions
Vaccine development has primarily focused on the patho-
genesis of a single microorganism based on its virulence and
immunoavoidance factors and the directed host response to
the monomicrobial infection. However, greater appreciation
of the fact that many infectious diseases result and persist
due to the polymicrobial nature and bioﬁlm maturation of
bacteria is challenging many perceptions on vaccine design.
Current recombinant vaccines targeting a single or a few
bacterial proteins possess the beneﬁts of easy manufacture,
no risk of disease from reversion back to a virulent form,
and few adverse effects from inﬂammatory induction com-
pared with whole-cell vaccines. Recombinant vaccine usage
does come with the loss of antigen diversity and robust
humoral response due to the innate response activation that
is provided from vaccination with whole cells. As such,
redundancy in bacterial proteins expressed during infection,
for example adhesins, subverts responses activated by
monovalent vaccines and provides incomplete protection.
Antigenic variation has also compelled reassessment of
vaccine design due to the observation that in vaccinated
individuals the diseases targeted by current clinical vaccines,
for example S. pneumoniae 7-valent, shift toward ones
actuated by previously scarce and inconsequential bacterial
variants that are not represented in the vaccine (Eskola et al.,
2001). Multivalent strategies have come to the forefront in
vaccine development in hopes to provide antigenic diversity
and sufﬁcient vaccine efﬁcacy, but some clinical trials with
multivalent vaccines fail to transition into a later phase, due
to the incomplete coverage against disease that is observed.
Staphylococcus aureus-mediated diseases highlight the key
properties of the pathogen that are challenges to current
vaccine strategies and not appropriately addressed during
most vaccine development efforts, including polymicrobial
infection, bioﬁlm maturation, and host carrier status. Vac-
cines targeting S. aureus adherence factors could be ineffec-
tive against diseases where coinfecting microorganisms
contribute virulence factors in trans and negate the activity
of the S. aureus factors, for example hypothetical control of
S. aureus adherence by the B. pertussis secreted proteins
during coinfection that mimics in vitro ﬁndings (Tuoma-
nen, 1986). Once S. aureus colonization is successful and
S. aureus immunoavoidance factors obstruct the innate
immune response, S. aureus may grow and persist as a
bioﬁlm community encapsulated in a polysaccharide ma-
trix. Compounding the problem is that this timed up- and
downregulated expression of virulence factors is not only
growth phase dependent but also disease speciﬁc.
The bioﬁlm phenotype further conceals S. aureus from
the immune system due to the downregulated expression of
factors that mediate initial infection and encapsulation in
polysaccharide that masks surface-associated proteins from
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bioﬁlm indicates that there is great heterogeneity in protein
expression throughout the bioﬁlm community, with protein
expression present in some microcolonies and completely
absent in others. As such, a vaccine that targeted these
proteins would be ineffective at eliciting an opsonization
response to clear S. aureus.
Another consideration for vaccine development is the
expression of virulence factors that antagonize the immune
response, inducing inﬂammation and tissue damage, where
further bacterial colonization can occur; other factors that
target and inactivate host immunoglobulins also pose
signiﬁcant problems. Knowledge of the speciﬁc immune
responses activated by the bacteria and whether that re-
sponse assists bacterial colonization and persistence will
allow the development of vaccines that can modulate the
immune response, using adjuvants or extrinsic bacterial
components, which skew toward appropriate immunity.
A ﬁnal consideration for vaccine development is S. aureus
carriage in humans. Analysis of sera from healthy carriers
establishes the circulation of anti-S. aureus immunoglobu-
lins, indicating that this response is insufﬁcient to prevent
colonization and persistence. Vaccine strategies using anti-
gens targeted by those immunoglobulins will probably elicit
a response that is not completely protective. Therefore,
screening for and removal of those antigens before protec-
tion studies may be advisable. Overall, these properties are
critical to understanding how the immune response is
ineffective at bacterial clearance. Further evaluation of these
features will establish optimal antigenic candidates, includ-
ing protein factors speciﬁc for disease and those not
concealed from the immune system that should be estab-
lished as prerequisites for S. aureus and other bacterial
vaccines.
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